FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092880198> ?p ?o ?g. }

• W2092880198 endingPage "1629" @default.
• W2092880198 startingPage "1619" @default.
• W2092880198 abstract "The lack of standardized criteria for measuring therapeutic response is a major obstacle to the development of new therapeutic agents for chronic graft-versus-host disease (cGVHD). National Institutes of Health (NIH) consensus criteria for evaluating therapeutic response were published in 2006. We report the results of 4 consecutive pilot trials evaluating the feasibility and estimating the interrater reliability and minimum detectable change of these response criteria. Hematology-oncology clinicians with limited experience in applying the NIH cGVHD response criteria (n = 34) participated in a 2.5-hour training session on response evaluation in cGVHD. Feasibility and interrater reliability between subspecialty cGVHD experts and this panel of clinician raters were examined in a sample of 25 children and adults with cGVHD. The minimum detectable change was calculated using the standard error of measurement. Clinicians’ impressions of the brief training session, the photo atlas, and the response criteria documentation tools were generally favorable. Performing and documenting the full set of response evaluations required a median of 21 minutes (range: 12-60 minutes) per rater. The Schirmer tear test required the greatest time of any single test (median: 9 minutes). Overall, interrater agreement for skin and oral manifestations was modest; however, in the third and fourth trials, the agreement between clinicians and experts for all dimensions except movable sclerosis approached satisfactory values. In the final 2 trials, the threshold for defining change exceeding measurement error was 19% to 22% body surface area (BSA) for erythema, 18% to 26% BSA for movable sclerosis, 17% to 21% BSA for nonmovable sclerosis, and 2.1 to 2.6 points on the 15-point NIH Oral cGHVD scale. Agreement between clinician-expert pairs was moderate to substantial for the measures of functional capacity and for the gastrointestinal and global cGVHD rating scales. These results suggest that the NIH response criteria are feasible for use, and these reliability estimates are encouraging, because they were observed following a single 2.5-hour training session given at multiple transplant centers, with no opportunity for iterative training and calibration. Research is needed to evaluate inter- and intrarater reliability in larger samples, and to evaluate these response criteria as predictors of outcomes in clinical trials. The lack of standardized criteria for measuring therapeutic response is a major obstacle to the development of new therapeutic agents for chronic graft-versus-host disease (cGVHD). National Institutes of Health (NIH) consensus criteria for evaluating therapeutic response were published in 2006. We report the results of 4 consecutive pilot trials evaluating the feasibility and estimating the interrater reliability and minimum detectable change of these response criteria. Hematology-oncology clinicians with limited experience in applying the NIH cGVHD response criteria (n = 34) participated in a 2.5-hour training session on response evaluation in cGVHD. Feasibility and interrater reliability between subspecialty cGVHD experts and this panel of clinician raters were examined in a sample of 25 children and adults with cGVHD. The minimum detectable change was calculated using the standard error of measurement. Clinicians’ impressions of the brief training session, the photo atlas, and the response criteria documentation tools were generally favorable. Performing and documenting the full set of response evaluations required a median of 21 minutes (range: 12-60 minutes) per rater. The Schirmer tear test required the greatest time of any single test (median: 9 minutes). Overall, interrater agreement for skin and oral manifestations was modest; however, in the third and fourth trials, the agreement between clinicians and experts for all dimensions except movable sclerosis approached satisfactory values. In the final 2 trials, the threshold for defining change exceeding measurement error was 19% to 22% body surface area (BSA) for erythema, 18% to 26% BSA for movable sclerosis, 17% to 21% BSA for nonmovable sclerosis, and 2.1 to 2.6 points on the 15-point NIH Oral cGHVD scale. Agreement between clinician-expert pairs was moderate to substantial for the measures of functional capacity and for the gastrointestinal and global cGVHD rating scales. These results suggest that the NIH response criteria are feasible for use, and these reliability estimates are encouraging, because they were observed following a single 2.5-hour training session given at multiple transplant centers, with no opportunity for iterative training and calibration. Research is needed to evaluate inter- and intrarater reliability in larger samples, and to evaluate these response criteria as predictors of outcomes in clinical trials." @default.
• W2092880198 created "2016-06-24" @default.
• W2092880198 creator A5000902340 @default.
• W2092880198 creator A5003078712 @default.
• W2092880198 creator A5007076896 @default.
• W2092880198 creator A5007983797 @default.
• W2092880198 creator A5011216248 @default.
• W2092880198 creator A5012202221 @default.
• W2092880198 creator A5016587367 @default.
• W2092880198 creator A5017952176 @default.
• W2092880198 creator A5027475930 @default.
• W2092880198 creator A5029365359 @default.
• W2092880198 creator A5031390636 @default.
• W2092880198 creator A5033904790 @default.
• W2092880198 creator A5041914870 @default.
• W2092880198 creator A5043494014 @default.
• W2092880198 creator A5046042231 @default.
• W2092880198 creator A5050639550 @default.
• W2092880198 creator A5053988910 @default.
• W2092880198 creator A5059063645 @default.
• W2092880198 creator A5065897197 @default.
• W2092880198 creator A5069919013 @default.
• W2092880198 creator A5070433963 @default.
• W2092880198 creator A5072068693 @default.
• W2092880198 creator A5085437967 @default.
• W2092880198 creator A5089893290 @default.
• W2092880198 creator A5091588185 @default.
• W2092880198 date "2011-11-01" @default.
• W2092880198 modified "2023-09-30" @default.
• W2092880198 title "A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus-Host Disease (cGVHD) Therapeutic Response Measures: Feasibility, Interrater Reliability, and Minimum Detectable Change" @default.
• W2092880198 cites W1981669564 @default.
• W2092880198 cites W1989403389 @default.
• W2092880198 cites W1997000848 @default.
• W2092880198 cites W1997148832 @default.
• W2092880198 cites W2008010728 @default.
• W2092880198 cites W2017616768 @default.
• W2092880198 cites W2018642809 @default.
• W2092880198 cites W2019386538 @default.
• W2092880198 cites W2025459079 @default.
• W2092880198 cites W2028590977 @default.
• W2092880198 cites W2048626722 @default.
• W2092880198 cites W2050257625 @default.
• W2092880198 cites W2053496236 @default.
• W2092880198 cites W2067724039 @default.
• W2092880198 cites W2071351610 @default.
• W2092880198 cites W2087506222 @default.
• W2092880198 cites W2102494802 @default.
• W2092880198 cites W2109346271 @default.
• W2092880198 cites W2118638289 @default.
• W2092880198 cites W2125130034 @default.
• W2092880198 cites W2133245934 @default.
• W2092880198 cites W2135149128 @default.
• W2092880198 cites W2136969865 @default.
• W2092880198 cites W2141160379 @default.
• W2092880198 cites W2141403362 @default.
• W2092880198 cites W2146295639 @default.
• W2092880198 cites W2150493928 @default.
• W2092880198 cites W2159681472 @default.
• W2092880198 cites W2164777277 @default.
• W2092880198 cites W2237649353 @default.
• W2092880198 cites W2618073389 @default.
• W2092880198 cites W3207243051 @default.
• W2092880198 cites W2103165277 @default.
• W2092880198 doi "https://doi.org/10.1016/j.bbmt.2011.04.002" @default.
• W2092880198 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3158826" @default.
• W2092880198 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21536143" @default.
• W2092880198 hasPublicationYear "2011" @default.
• W2092880198 type Work @default.
• W2092880198 sameAs 2092880198 @default.
• W2092880198 citedByCount "57" @default.
• W2092880198 countsByYear W20928801982012 @default.
• W2092880198 countsByYear W20928801982013 @default.
• W2092880198 countsByYear W20928801982014 @default.
• W2092880198 countsByYear W20928801982015 @default.
• W2092880198 countsByYear W20928801982016 @default.
• W2092880198 countsByYear W20928801982017 @default.
• W2092880198 countsByYear W20928801982018 @default.
• W2092880198 countsByYear W20928801982019 @default.
• W2092880198 countsByYear W20928801982020 @default.
• W2092880198 countsByYear W20928801982021 @default.
• W2092880198 countsByYear W20928801982022 @default.
• W2092880198 countsByYear W20928801982023 @default.
• W2092880198 crossrefType "journal-article" @default.
• W2092880198 hasAuthorship W2092880198A5000902340 @default.
• W2092880198 hasAuthorship W2092880198A5003078712 @default.
• W2092880198 hasAuthorship W2092880198A5007076896 @default.
• W2092880198 hasAuthorship W2092880198A5007983797 @default.
• W2092880198 hasAuthorship W2092880198A5011216248 @default.
• W2092880198 hasAuthorship W2092880198A5012202221 @default.
• W2092880198 hasAuthorship W2092880198A5016587367 @default.
• W2092880198 hasAuthorship W2092880198A5017952176 @default.
• W2092880198 hasAuthorship W2092880198A5027475930 @default.
• W2092880198 hasAuthorship W2092880198A5029365359 @default.
• W2092880198 hasAuthorship W2092880198A5031390636 @default.
• W2092880198 hasAuthorship W2092880198A5033904790 @default.
• W2092880198 hasAuthorship W2092880198A5041914870 @default.
• W2092880198 hasAuthorship W2092880198A5043494014 @default.
• W2092880198 hasAuthorship W2092880198A5046042231 @default.

• next